Corvus Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Corvus Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2016 to Q3 2024.
  • Corvus Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 54.1 %, a 185% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 54.1 +35.1 +185% Sep 30, 2024
Q2 2024 20.6 -0.21 -1.01% Jun 30, 2024
Q1 2024 18 -1.74 -8.83% Mar 31, 2024
Q4 2023 17.9 +0.17 +0.96% Dec 31, 2023
Q3 2023 19 +3.38 +21.7% Sep 30, 2023
Q2 2023 20.8 +7.37 +54.7% Jun 30, 2023
Q1 2023 19.7 +6.57 +50% Mar 31, 2023
Q4 2022 17.7 +3.89 +28.2% Dec 31, 2022
Q3 2022 15.6 +0.52 +3.46% Sep 30, 2022
Q2 2022 13.5 -4.45 -24.8% Jun 30, 2022
Q1 2022 13.1 -8.07 -38.1% Mar 31, 2022
Q4 2021 13.8 -10.1 -42.3% Dec 31, 2021
Q3 2021 15.1 -8.64 -36.5% Sep 30, 2021
Q2 2021 17.9 -1.77 -8.99% Jun 30, 2021
Q1 2021 21.2 +4.01 +23.3% Mar 31, 2021
Q4 2020 24 +9.43 +64.9% Dec 31, 2020
Q3 2020 23.7 +11.9 +101% Sep 30, 2020
Q2 2020 19.7 +9.84 +99.8% Jun 30, 2020
Q1 2020 17.2 +8.8 +105% Mar 31, 2020
Q4 2019 14.5 +6.78 +87.5% Dec 31, 2019
Q3 2019 11.8 +3.21 +37.3% Sep 30, 2019
Q2 2019 9.86 +0.16 +1.65% Jun 30, 2019
Q1 2019 8.4 -1.86 -18.1% Mar 31, 2019
Q4 2018 7.75 -2.36 -23.4% Dec 31, 2018
Q3 2018 8.6 +0.16 +1.89% Sep 30, 2018
Q2 2018 9.7 +2.92 +43.1% Jun 30, 2018
Q1 2018 10.3 +5.13 +99.9% Mar 31, 2018
Q4 2017 10.1 +6 +146% Dec 31, 2017
Q3 2017 8.45 +3.58 +73.6% Sep 30, 2017
Q2 2017 6.77 Jun 30, 2017
Q1 2017 5.13 Mar 31, 2017
Q4 2016 4.11 Dec 31, 2016
Q3 2016 4.87 Sep 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.